A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.
Zacks.com on MSN8h
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
Wells Fargo analyst Derek Archila maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...
Indian benchmark indices Nifty 50 and Sensex ended lower in the previous trade session. Nifty 50 closed at 25,057.35, while Sensex ended at 81,820.12. Overnight, Wall Street indices tumbled from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback